May 08, 2025

FDA Warns Physicians of Tianeptine Dangers

The FDA warns physicians about unapproved tianeptine products that are linked to severe adverse events, including dependence, toxicity, and death.

Conexiant

May 08, 2025

Diet Patterns Affect Menarche Timing

New research reveals healthier diets delay menarche while inflammatory diets accelerate it, potentially impacting long-term health outcomes in women regardless of BMI.

Conexiant

May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters

May 07, 2025

FDA Approves Low-Dose Chlorthalidone Tablet

The FDA has approved HemiClor, a 12.5-mg chlorthalidone tablet, providing patients with a low-dose option.

Conexiant

May 06, 2025

FDA Approves TAVR Platform for Asymptomatic AS

The FDA has approved the SAPIEN 3 TAVR platform for patients with asymptomatic severe aortic stenosis based on data from the EARLY TAVR trial.

Conexiant

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

May 05, 2025

True Heart Age Beyond Birthdays

New research uses cardiac MRI to calculate "functional heart age," showing obesity and other risk factors can age the heart by decades.

Conexiant

May 01, 2025

Phthalates Linked to Cardiovascular Mortality Globally

Researchers linked di-2-ethylhexylphthalate plastic exposure to over 350,000 cardiovascular deaths and 10 million years of life lost, supporting calls for international regulatory measures.

Conexiant

May 01, 2025

FDA Approves Intranasal DHE for Acute Migraine Relief

The FDA has approved Atzumi for the acute treatment of migraine with or without aura in adults.

Conexiant